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Efficient CRISPR/Cas9-assisted gene targeting enables rapid and
precise genetic manipulation of mammalian neural stem cells
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Claudia Garcia-Diaz1, Carla Blin1, Vivien Grant1, Harry Bulstrode1, Sabine Gogolok1, William C. Skarnes2 and
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ABSTRACT
Mammalian neural stem cell (NSC) lines provide a tractable model for
discovery across stem cell and developmental biology, regenerative
medicine and neuroscience. They can be derived from foetal or adult
germinal tissues and continuously propagated in vitro as adherent
monolayers. NSCs are clonally expandable, genetically stable, and
easily transfectable – experimental attributes compatible with
targeted genetic manipulations. However, gene targeting, which is
crucial for functional studies of embryonic stem cells, has not been
exploited to date in NSC lines. Here, we deploy CRISPR/Cas9
technology to demonstrate a variety of sophisticated genetic
modifications via gene targeting in both mouse and human NSC
lines, including: (1) efficient targeted transgene insertion at safe
harbour loci (Rosa26 and AAVS1); (2) biallelic knockout of
neurodevelopmental transcription factor genes; (3) simple knock-in
of epitope tags and fluorescent reporters (e.g. Sox2-V5 and Sox2-
mCherry); and (4) engineering of glioma mutations (TP53 deletion;
H3F3A point mutations). These resources and optimised methods
enable facile and scalable genome editing in mammalian NSCs,
providing significant new opportunities for functional genetic analysis.
KEY WORDS: Neural stem cell, CRISPR/Cas9, Genome editing,
Gene targeting, Epitope tagging, Homologous recombination,
Glioblastoma, Transcription factor
INTRODUCTION
Targeted editing of endogenous genes via homologous
recombination (HR) – termed gene targeting – has been widely
deployed in studies of pluripotent stem cells, most notably mouse
embryonic stem cells (ESCs) (Capecchi, 2005). Complex genetic
manipulations in these cells is made possible by their inherent
experimental attributes: they can be expanded to large numbers
without genetic transformation; they are easily transfected, enabling
efficient delivery of exogenous DNA; they can undergo HR; and,
perhaps most importantly, they can be selectively propagated by
clonal expansion in order to isolate defined genetic variants (Glaser
et al., 2005). Such properties have underpinned a repertoire of
genetic engineering technologies, including gene knockouts,
conditional mutagenesis, and endogenous protein tagging. This
has transformed our ability to explore mammalian gene function.
Similarly, the in vitro culture of neural stem cells (NSCs) and
neural progenitor cells – of various distinct classes – has proven to
be a valuable experimental approach for exploring molecular
processes controlling self-renewal and differentiation across
development, tissue homeostasis, and in disease models of the
central nervous system (CNS) (Gage and Temple, 2013). NSC lines
display molecular hallmarks of forebrain radial glia and can be
readily established and expanded as adherent monolayers, either
following in vitro differentiation of pluripotent cells, or more
directly by primary culture of germinal tissues from the developing
and adult mammalian CNS (Conti and Cattaneo, 2010; Conti et al.,
2005; Pollard et al., 2006). These tissue stem cells can be routinely
propagated and clonally expanded as primary stem cell lines
in the absence of spontaneous differentiation and/or genetic
transformation, thereby providing an experimentally tractable
somatic stem cell model.
Genetically normal NSC lines have proven particularly useful in
studies in which large numbers of tissue-restricted stem cells are
needed, such as biochemical analyses (Engelen et al., 2011),
transcriptome profiling (Johnson et al., 2008; Webb et al., 2013),
genome-wide mapping of chromatin modifications, DNA
methylation and transcription factor binding (Bernstein et al.,
2006; Caren et al., 2015; Meissner et al., 2008; Mikkelsen et al.,
2007), and chemical or genetic screening (Diamandis et al., 2007;
Hubert et al., 2013). Importantly, malignant cells displaying
phenotypic and functional properties analogous to NSCs can also
be isolated from glioblastoma (GBM) patient samples using similar
culture conditions (Pollard et al., 2009; Singh et al., 2004). This
enables comparison of genetically normal NSCs with their
malignant GBM counterparts, which has been helpful in defining
tumour-specific vulnerabilities (Danovi et al., 2013; Ding et al.,
2013; Hubert et al., 2013; Pollard et al., 2009).
Despite experimental attributes that are analogous to ESC
cultures, targeted genetic manipulations directly in mammalian
NSC lines have not yet been reported. Gene targeting has been
notoriously difficult in most somatic cell types owing to the
inefficiency of HR. However, recent improvements in design and
production of customisable nucleases capable of introducing site-
specific DNA double-strand breaks (DSBs) have provided
increasingly refined and reliable ways to manipulate the
mammalian genome (Mali et al., 2013). Once introduced, DSBs
are able to trigger endogenous homology-directed repair (HDR)
mechanisms, thereby increasing gene targeting efficiencies at a
locus of interest when an exogenously introduced repair template is
delivered. Alternatively, DSBs can be repaired through the error-
prone non-homologous end-joining (NHEJ) pathway, which
normally results in random insertion or deletion (indel) mutationsReceived 6 June 2016; Accepted 15 December 2016
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(Hsu et al., 2014). Therefore, in addition to facilitating gene
targeting by HR, DSBs result in site-specific mutagenesis.
Among the different platforms described for introduction of site-
specific DSBs in eukaryotic cells, the clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 system has
emerged as the favoured technology (Hsu et al., 2014). Derived
from the prokaryotic adaptive immune system, this consists of an
RNA-guided endonuclease (Cas9) able to generate DSBs efficiently
using Watson–Crick base pairing to identify target DNA (Jinek
et al., 2012). CRISPR/Cas9 has been adapted for mammalian
genome editing purposes through human codon optimisation of
Cas9 and generation of chimeric single guide RNAs (sgRNAs)
(Mali et al., 2013). The Cas9 has also been further modified by
mutation of one of the two independent nuclease domains in order
to generate a nickase variant (Cas9n), which provides greater target
specificity when used with a pair of strand-specific sgRNAs
(Ran et al., 2013).
Here, we exploited the CRISPR/Cas9 technology to demonstrate
complex and precise genetic manipulations in bothmouse and human
NSC lines. We find that CRISPR/Cas9-assisted gene targeting in
NSCs is highly efficient, easy to implement, and scalable. Optimised
strategies and protocols were developed to support a range of targeted
genetic manipulations, such as gene knockouts, knock-ins of epitope
tags and fluorescent reporters, and delivery of disease-relevant
mutations. As an example of the potential of this new technology, we
focused our efforts on genes encoding neurodevelopmental
transcription factors, given the wide interest in these across stem
cell biology, reprogramming, regenerative medicine and neuro-
oncology.
RESULTS
Mouse and human NSC cultures can undergo gene targeting
via Cas9-assisted homologous recombination at ‘safe-
harbour’ loci
Genomic safe harbours are known to undergo efficient HR in ESCs
and induced pluripotent stem cells (iPSCs) and enable predictable
expression of exogenous DNA elements across various cell types.
To determine first whether mouse and human NSCs were amenable
to Cas9-assisted gene targeting, we focused on the widely used safe
harbour loci mouse Rosa26 and human AAVS1. Targeting vectors
with 1 kb homology arms flanking a constitutive Luciferase-2A-
GFP-IRES-BSD expression cassette were produced and tested in an
adult mouse NSC line (ANS4) and a human foetal NSC line (U3)
(Fig. 1A,B; Fig. S1). Two matching CRISPR sgRNAs were
designed to lie in close proximity and target opposite strands of each
locus and could therefore be used as a pair with the Cas9n.
Transient plasmid transfection of Cas9n and sgRNA pairs was
performed and GFP-expressing cells were isolated using
fluorescence-activated cell sorting (FACS) 10-15 days after
transfection and drug selection (Fig. 1B,C). PCR-based
genotyping of the sorted population indicated successful targeted
insertion of the expression cassette into Rosa26 and AAVS1 loci, and
the majority of cells stably expressed high levels of GFP (>80%,
visualised by microscopy) and luciferase (Fig. 1D-F). To determine
the precise efficiency of correct insertion, clonal lines were
generated from the sorted population using improved colony
formation conditions (see Materials and Methods) and PCR
genotyped (Fig. S2A). We achieved targeting efficiencies of
∼23% (11/48) and ∼16% (3/19) in mouse and human NSCs,
respectively. Similar efficiency was achieved in a freshly derived
foetal forebrain mouse NSC line (FNS2; Fig. S2B). Further PCR
screening did not detect vector backbone sequences and qPCR copy
number analysis indicated single copy integration in the majority of
correctly targeted Rosa26 clones (Fig. S2C,D). Genome-edited
clonal lines proliferated normally, and uniformly expressed GFP
and the known NSC markers nestin and Sox2. Diploid karyotype as
well as glial and neuronal potential was maintained after continuous
in vitro expansion (Fig. S2E,F).
Both Rosa26-Luc-GFP and AAVS1-Luc-GFP targeting vectors
were constructed using intermediate vectors compatible with the
Gateway cloning system (Fig. S3A). This strategy enables
straightforward exchange of alternative cargos, which we
exemplified by the generation a CAG promoter-driven Cas9-2A-
GFP vector for targeting the Rosa26 locus (Fig. 1G). Delivery of
this construct into mouse NSCs enabled facile isolation of NSCs
constitutively expressing Cas9 (termed CAS9-NSCs; used later in
this study) using FACS (Fig. 1H,I). A similar strategy for targeting
AAVS1 also enabled rapid generation of Tet-inducible-GFP-
expressing human NSCs (Fig. S3B-D).
Altogether, these results demonstrate that both mouse and human
NSCs can undergo Cas9-assisted gene targeting and that promoter-
driven expression cassettes can be efficiently knocked into safe
harbour loci by HR. This has practical value, as it circumvents two
issues – insertional mutagenesis and transgene silencing – that are
often associated with conventional transgenic approaches (e.g. viral
vectors or transposase delivery systems).
Efficient biallelic disruption of Olig2 in mouse NSCs using
Cas9-induced NHEJ
Targeted inactivation of endogenous genes via deletion or mutation
of coding sequences is the standard reverse genetics used to define
gene function. Unlike RNAi technologies, loss of the gene product
is unequivocal and permanent, and risks of undesirable non-specific
effects are minimised. We therefore tested whether the CRISPR/
Cas9 system could be used to disrupt gene expression efficiently in
mouse NSC lines by site-specific mutagenesis.
For this purpose, we focused on Olig2, a known NSC
transcriptional regulator that is highly expressed in mouse NSC
lines (Ligon et al., 2007). A pair of sgRNAs targeting the Olig2
coding sequence and Cas9n-2A-GFP expression plasmids were
transiently delivered into mouse NSCs, and successful transfectants
were harvested by FACS (Fig. 2A). Formation of indel mutations
around the sgRNA target sites was confirmed using the T7
endonuclease I (T7EI) assay (Fig. 2B). The frequency of biallelic
mutations that result in loss of the Olig2 protein product was
assessed by immunocytochemistry (ICC) with a specific Olig2
antibody. Using this strategy, we observed biallelic inactivation
efficiencies of ∼7% in unsorted cells, and up to ∼25% in the sorted
fraction (Fig. 2B,C). A similar frequency of Olig2-negative colonies
was observed when the transfected cells were clonally expanded
(32%, n=25; not shown). Similar efficiencies could be achieved
using the independent foetal forebrain NSC line FNS2 (Fig. S4A).
Recent evidence suggests that Cas9 off-target cleavage is not as
pervasive as initially feared and can be minimised using appropriate
sgRNA design rules (Kim et al., 2016). We therefore tested thewild-
type Cas9 (WTCas9-2A-GFP), rather than the nickase, as this
provides a more convenient strategy. The two sgRNAs (predicted to
target unique genomic sites; see Materials and Methods) were
delivered separately and, following FACS enrichment, we noted that
significantly higher efficiencies could be achieved to the Cas9n
(Fig. S4B). Thus, both Cas9 and Cas9n can work effectively, with
the latter being useful if unique gRNAs are unavailable.
We next delivered the individual sgRNA plasmids into our newly
generated CAS9-NSC line to test whether even higher levels of
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Fig. 1. Mouse and human NSCs are
amenable to CRISPR/Cas9-mediated gene
targeting. (A) Schematic of the experimental
strategy for generating constitutive Luciferase
(Luc)-GFP expressing mouse and human
NSCs by gene targeting at the safe harbour loci
Rosa26 or AAVS1. Targeting vectors contained
the CAG-Luc-2A-GFP tethered by an IRES to a
blasticidin resistance cassette (BSD); the
expression cassettes were flanked by ∼1 kb
long homology arms. (B) Schematic depiction
of the targeting strategy for the Rosa26 (left)
and AAVS1 loci (right). Exons are shown as
dark grey blocks. Light grey rectangles indicate
the location of the homology arms flanking the
expression cassette (L-HA, left homology arm;
R-HA, right homology arm). CRISPR sgRNA
target sites are indicated with yellow triangles.
Horizontal arrows indicate genotyping PCR
primers used to confirm on-target integration of
the expression cassette. (C) Using FACS,
targeted cells were enriched on the basis of
GFPexpression after blastidicin selection.Wild-
type non-transfected mouse and human NSCs
were used as a control to set gates for cell
sorting. SSC, side scatter. (D) PCR-based
genotyping using primer sets 1 and 2 (depicted
in A) confirmed correct targeted integration of
the CAG-Luc-2A-GFP cassette into theRosa26
and AAVS1 loci. Non-transfected parental cells
were used as negative control for the
genotyping. (E) Representative live phase
contrast and wide-field fluorescence
microscopy images of sorted GFP-positive
mouse and human NSCs. Scale bar: 100 μm.
(F) Luciferase levels were determined using a
microplate reader and confirmed functionality of
the targeted cassette in both mouse and human
cells. (G) Schematic of the Gateway cloning-
based strategy for repurposing targeting
vectors with different cassettes of interest. In
the example shown, the Luc-2A-GFP in the
Rosa26 targeting vector is replaced by a Cas9-
GFP expression cassette via LR Gateway
cloning. (H) Mouse NSCs were transfected with
the Rosa26 Cas9-GFP targeting vector and
enriched by FACS on the basis of GFP
expression. (I) PCR-based genotyping (top)
confirms correct insertion of Cas9-GFP
expression cassette at the Rosa26 locus;
western immunoblotting (bottom) confirms high
levels of Cas9 protein expression in a clonal
NSC line derived from the GFP-sorted cells.
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mutations were possible (Fig. 2D). The T7EI assay indicated indel
formation around the predicted cutting site, thereby confirming the
activity of the constitutively expressed Cas9 (Fig. 2E). Remarkably,
using this approach we achieve knockout efficiencies of around
>50% for each sgRNA (Fig. 2E,F). Altogether, these results
demonstrate the power of CRISPR/Cas9 to enable efficient biallelic
disruption ofOlig2 via NHEJ in mouse NSCs. This can be achieved
either by transient plasmid delivery of Cas9 or with increased
efficiency using the constitutive Cas9-expressing NSC line.
Efficient generation of Olig2 knockout NSC lines using
CRISPR/Cas9-assisted gene targeting
Despite the value in generating random indels by NHEJ, a more
precise and flexible approach to manipulating endogenous genes is
provided by HR-based gene targeting. This offers complete control
over the type of allele to be generated and enables removal or
replacement of any desired sequence. To test whether this was
possible in mouse NSCs, we employed a gene targeting strategy
recently developed for human iPSCs (W.C.S., unpublished). A
selectable marker is used to replace a target exon of interest, thereby
enabling enrichment for correctly targeted cells; these then emerge
as discrete resistant colonies that can be selectively propagated
and genotyped. Provided that biallelic cleavage is possible
and DSBs are likely to be repaired more frequently by NHEJ
than by HDR mechanisms, we anticipated that the most frequent
type of editing event would be targeted replacement of one allele
with the selectable marker, and generation of indels at the other.
Thus, biallelic loss-of-function mutations might emerge from a
single round of transfection and selection. Importantly, this
approach does not require cell sorting or Cas9-expressing
transgenic lines, and genotyping of clones is simplified by the
fact that the indel-containing allele can be directly sequenced from
the PCR reaction.
We first focused on the mouse NSC regulator Olig2, attempting
to replace its single coding exon with an Ef1α-puromycin (Ef1α-
PuroR) selection cassette and assessing the presence of indel
mutations on the second allele (Fig. 3A,B). The sgRNA pair
described above was used together with a newly generated targeting
vector with 1 kb long homology arms flanking the Ef1α-PuroR
cassette. This was generated via production of a Gateway cloning
compatible intermediate vector, as described for Rosa26 and AAVS1
vectors.
Fig. 2. Olig2 knockout in mouse NSCs via CRISPR/
Cas9-induced NHEJ repair. (A) Experimental strategy
for Olig2 deletion in wild-type (WT) mouse NSCs using
transient plasmid delivery. Cells were transiently
transfected with the CRISPR sgRNA pair (target site
shown as yellow triangles) together with a Cas9n-2A-GFP
plasmid. Transfected cells were enriched by FACS on the
basis of GFP expression. (B) Generation of indel
mutations in the transfected cells was assessed using a
T7EI cleavage assay. Larger arrow indicates the predicted
WT/uncleaved PCR product; smaller arrows indicate
T7EI-cleaved fragments used to estimate indel frequency.
(C) ICC was used to determine the frequency of Olig2-
negative cells, which result from biallelic frameshift
mutations (white arrowheads). Graph shows percentage
of Olig2-negative cells relative to total DAPI-stained
nuclei. Scale bar: 50 µm. (D,E) Experimental strategy for
Olig2 deletion in the CAS9 NSC line. Cells were
transfected with the two CRISPR sgRNAs individually (D)
and cleavage at target site confirmed by the T7E1 assay
(E). (F) Efficiency of biallelic knockout was quantified by
ICC for Olig2. Scale bar: 50 µm.
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Mouse NSCs were transfected with the circularised targeting
vector alone or in combination with Cas9n/sgRNAs plasmids, and
treated with puromycin. Resistant NSC colonies emerged within
7 days (Fig. 3C), and PCR genotyping of pooled colonies was used
to verify correct targeting at the Olig2 locus (Fig. 3D). Importantly,
correct replacement of the Olig2 coding sequence by the Ef1α-
PuroR cassette was only achieved when both the Cas9n and
sgRNAs were co-transfected, thus confirming the need for the
CRISPR/Cas9 system to achieve efficient HR in NSCs (Fig. 3D). As
anticipated, using a T7EI assay we also observed formation of indels
around the sgRNA cutting site, which are likely associated with
NHEJ events within the non-targeted allele (Fig. 3D).
Fig. 3. CRISPR/Cas9-mediated homologous
recombination enables facile knockout of
transcription factor genes in mouse NSCs.
(A) Schematic of the experimental strategy to
knock out Olig2 via CRISPR/Cas9-assisted gene
targeting. Targeted cells are enriched by
puromycin selection and should emerge as
discrete NSC colonies. Biallelic knockout clones
are expected to have one allele replaced by the
Ef1α-PuroR cassette and the second allele
damaged by an indel mutation (yellow rectangle)
at the CRISPR sgRNA cutting site (yellow
triangle). (B) Representation of the mouse Olig2
locus (top), and predicted targeted alleles
following HDR (middle) or NHEJ (bottom). Olig2
coding sequence is shown in dark grey. Adjacent
white rectangles represent untranslated regions
(5′ and 3′ UTR). PCR genotyping (PCR1 and 2,
left and right arms, respectively) were designed
with primers within the Ef1α-PuroR cassette and
outside of the homology arms (light grey
rectangles). PCR3 product could be used in a
T7EI assay or Sanger sequencing to confirm the
presence of indels in the NHEJ allele.
(C) Representative phase contrast image of
exemplar puromycin-resistant NSC colony, which
emerged after transfection with Olig2 targeting
vector. Scale bars: 200 µm. (D) PCR genotyping
of pooled puromycin-resistant colonies after
transfection with Olig2 targeting vector (Ef1α-
PuroR TV) alone or in combination with CRISPR
Cas9 nickase and/or sgRNA pair. PCR1 and
PCR2 were used to confirm correct HR event at
Olig2 locus (top and middle); T7EI assay for
checking NHEJ-mediated damaged at the sgRNA
targeted site (bottom). (E) Representative
genotyping PCR results of ten puromycin-
resistant clones, picked and expanded as clonal
lines following transfection with targeting vector
and CRISPR/Cas9 components. (F) Summary of
types of indel mutations identified by Sanger
sequencing of PCR3 product (shown in B) in
correctly targeted Olig2 clones. Wild type, no
indel; in frame, 3N; frame shift, 3N+1 or 3N+2.
(G) Representative Sanger sequencing trace of
one Olig2 targeted clone showing 10 bp insertion
within the remainingOlig2 coding exon. (H) ICC in
wild-type parental cells and Olig2 clone
harbouring the 10 bp insertion confirms complete
ablation of the Olig2 protein. Scale bar: 50 µm.
(I) Scale-up of the same strategy used forOlig2 in
14 other transcription factors and frequency of
indel types present on the second allele of
correctly targeted clones. Mosaics contained
more than one indel within the same clone and
were identified by mixed Sanger sequencing
traces (see Fig. S5B).
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To determine targeting efficiencies and the precise status of each
allele, puromycin-resistant colonies were picked and expanded as
clonal NSC lines. PCR-based genotyping confirmed correct
targeting at the Olig2 locus in ∼26% of the screened clones
(n=112; Fig. 3E). Biallelic replacement of the Olig2 coding exon
was not observed, as PCR with internal primers was in all cases able
to amplify the non-targeted allele (Fig. 3E). Nevertheless, Sanger
sequencing of the PCR products revealed a remarkably high
frequency of indel mutations within the remaining allele of correctly
targeted clones (n=16/29; Fig. 3F,G), thereby demonstrating the
value of the strategy for efficient generation of biallelic mutants.
Complete ablation of Olig2 protein levels was confirmed by ICC
and western blot (WB) in the clones harbouring frame-shifting
indels (i.e. 3N+1 or 3N+2) (Fig. 3G,H; Fig. S5A). The edited clonal
lines were diploid, maintained NSC morphology and nestin
expression, and proliferated similarly to parental controls
(Fig. S5B). qPCR copy number analysis indicated single insertion
of the Ef1α-Puro cassette in the majority of correctly targeted clones
(Fig. S6A).
We also knocked out Olig2 by gene targeting in a PDGFRα-
H2B-GFP reporter NSC line (PG1-1) derived from a previously
generated mouse strain (Hamilton et al., 2003). PDGFRα is a
marker of oligodendrocyte progenitor cells and is activated as NSCs
undergo differentiation. Puromocyin-resistant colonies were
generated and, consistent with its known role, we found that
Olig2-negative NSC colonies failed to give rise to GFP-positive
oligodendrocyte precursor cells when triggered to differentiate
(Fig. S7).
Together, these data demonstrate that generation of NSC lines
with biallelic loss of function by gene targeting is highly efficient in
mouse NSC lines. Remarkably, this can be achieved with only a
single round of transfection and screening of a handful of clones,
thereby greatly simplifying reverse genetics in NSCs.
A scalable strategy for generating mutant alleles in mouse
NSCs using CRISPR/Cas9-assisted gene targeting
To determine whether the observed high knockout efficiency was
unique to Olig2 we next assessed gene targeting for a further three
neurodevelopmental transcription factor genes: Cebpb, Ascl1 (also
known as Mash1) and Sox2 (Carro et al., 2010; Castro et al., 2011;
Gómez-López et al., 2011). The coding sequences of these genes
also lie within a single exon, thereby facilitating their complete
ablation. Utilising the same gene-targeting strategy and delivery
methods as for Olig2 (Cas9n plus Ef1α-PuroR vector), an even
higher targeting efficiency was achieved for Cebpb (∼57%; n=88).
The majority of correctly targeted clones also harboured indel
mutations at the non-targeted allele (36/50; biallelic mutation
efficiency 72%). By comparison, for Ascl1 we observed lower
targeting efficiency (13.6%) and frequency of biallelic mutations
(1.5%; n=66). However, simply switching to wild-type Cas9
significantly increased the frequency of Ascl1 targeted clones and
presence of indels within their second alleles (∼35 and ∼30%,
respectively; n=86) (Table 1; Fig. 3I). Approximately 70% of
correctly targeted Cebpb and Ascl1 clones showed single-copy
transgene integration as confirmed by qPCR copy number analysis
(Fig. S6A).
Sox2 is required for in vitro NSC self-renewal (Gómez-López
et al., 2011), and therefore recovery of expandable NSC clones with
biallelic mutations and consequent loss of function should not be
possible. To achieve targeting at the Sox2 locus, we tested sgRNA
pairs lying near to either the start or the stop codon (sgRNA pair 1-2
and 3-4, respectively) in combination with Cas9n or wild-type
Cas9. As anticipated, only a limited number of puromycin-resistant
NSC colonies emerged, and low targeting efficiencies ranging from
∼1.3% to ∼9.0% (n=79 and n=22, respectively) were achieved
(Table 1). Importantly, biallelic knockout was not observed. The
recovered targeted clones contained no damage or only small in-
frame indels on the second allele (Fig. 3I; Fig. S8), confirming the
essential role of Sox2 in NSC colony formation. Failure to recover
loss-of-function mutations on the NHEJ-damaged allele thereby
provides unbiased functional genetic evidence that a gene is
necessary for NSC self-renewal.
To enable medium throughput experiments, we optimised
conditions to allow parallel transfection of 16 samples using
reduced cell numbers and DNA amount with the Amaxa 4D system
(Lonza) (see Materials and Methods). We designed and built
targeting vectors and matched sgRNA pairs to knock out a set of 16
candidate regulators of NSC self-renewal, chosen as potential Sox2
downstream transcriptional targets (Lodato et al., 2013; S.M.P. and
H.B., unpublished). Wild-type Cas9 was used in these experiments
to maximise recovery of targeted clones. We found that efficient
targeting can be achieved using only 400,000 cells and <1 µg of
plasmid DNA (Fig. S9).
Using these optimised conditions, we targeted 16 genes in a
single experiment, with mutant clones obtained, expanded and
genotyped within 3 weeks. Eleven of these were successfully
targeted (Olig2, Nfe2l2, Klf7, Rorc, Foxj3, Fos, Hoxa5, Lhx2,
Trp73, Klf6, Hes6), with efficiencies ranging from 5 to 56% and
loss-of-function mutants recovered in most of the cases (Table 1;
Fig. 3I; Fig. S8). Thus, biallelic knockouts can be routinely
generated by Cas9-assisted gene targeting in an efficient and
scalable manner in mouse NSCs.
Knock-in of a fluorescent reporter to generate Sox2-mCherry
reporter NSCs
Knock-in of fluorescent reporters to generate in-frame fusion
proteins provides a useful experimental approach to monitor levels
and localisation of a specific gene product. Such a strategy has been
widely deployed in ESCs and iPSCs to allow real-time observation
of gene-expression dynamics, cell-lineage tracing, and isolation of a
specific cell population of interest from differentiating cultures or
embryos (Goulburn et al., 2011; Ying et al., 2003).
To test whether fluorescent reporters could be knocked in using
CRISPR/Cas9-assisted gene targeting in mouse NSCs, we focused
on Sox2. We designed an antibiotic-selection free strategy in which
an mCherry fluorescent reporter cassette, plus a small flexible
linker, is introduced at the Sox2 C terminus, creating a new Sox2-
mCherry fusion protein product (Fig. 4A). The targeting vector was
promoterless, and consequently mCherry signal can only arise from
the correct, in-frame insertion at the endogenous Sox2 locus.
Cells were transfected with the targeting vector together with the
Cas9n and a pair of sgRNAs that cut in the 3′UTR sequence
adjacent to the stop codon (sgRNAs 5-6). After 10 days, ∼1% of
cells were identified as mCherry positive and isolated by FACS
(Fig. S10A). Wide-field immunofluorescence microscopy
confirmed nuclear localisation of the mCherry in live cells; this
colocalised with Sox2 antibody staining by ICC (Fig. 4C,D;
Fig. S10B). Clonal lines were subsequently derived from the sorted
mCherry-positive subpopulation and PCR-genotyped (Fig. 4E).
From 23 clones screened, 20 were correctly targeted at the Sox2
locus (∼87% targeting efficiency). Notably, biallelic targeting to
create homozygous reporters was achieved with high efficiency
(∼26%; n=6/23). Flow cytometry analysis confirmed uniform
mCherry expression in a homozygous targeted Sox2-mCherry NSC
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clonal line (Fig. 4F). This proliferated normally, displayed NSC
morphology and nestin expression and had a diploid karyotype
(Fig. S10C,D). Together, these results demonstrate the power
of Cas9-assisted HR for facile knock-in of fluorescent protein
reporters at endogenous genes in NSCs, and highlight the value of
promoterless targeting vectors to isolate biallelic targeted cells.
Efficient knock-in of epitope tags using single-stranded
oligonucleotide donor templates
Epitope tagging involves fusion of a small peptide (e.g. V5, FLAG,
HA or MYC) to the protein of interest. This simplifies
immunoprecipitation, immunoblotting and immunocytochemistry,
and is highly desirable when good quality antibodies are
unavailable. The approach, however, has been mainly limited to
ectopically expressed transgenes, with the attendant limitations of
their non-physiological levels of expression. Knock in of epitope
tags to endogenous genes therefore represents a more attractive
experimental approach and has been widely employed in model
organisms, such as Saccharomyces cerevisiae, in which HR is
highly efficient (Ghaemmaghami et al., 2003). Recently, this has
also been reported in mammalian ESC and cancer cell lines through
CRISPR/Cas9-assisted gene editing (Savic et al., 2015; Yang et al.,
2013). We therefore assessed whether knock-in of epitope tags to
endogenous genes could be achieved in mouse NSC lines and
developed optimised protocols for this purpose.
Because of the reduced length of coding sequences for epitope
tags, we opted to use short oligodeoxynucleotides as a donor
template, thus avoiding the need for targeting vector production.
Initially, we attempted to insert a V5 tag intoOlig2 and Sox2 using a
strategy previously described in human ESC cultures (Ran et al.,
2013). This relies on NHEJ-based insertion of double-stranded
oligodeoxynucleotide (dsODN) donors containing overhangs
compatible with Cas9n-induced double nicking. Although ICC
identified clear V5 nuclear staining in ∼1.5% of cells, unfortunately
this strategy was undermined by the persistent emergence of
undesirable flanking indels in the resulting clonal lines (data not
shown).
A simpler alternative strategy was therefore pursued, wherein
single-stranded ∼185-nt long oligodeoxynucleotides (ssODN) were
used as repair templates. These comprised 45 nucleotides of a V5 tag
sequence flanked by 70-nt long homology arms. To avoid disruption
of endogenous gene-coding sequences, gRNAs were designed to
target the 3′UTR region proximal to the stop codons (Fig. 5A). The
protospacer adjacent motif (PAM) sequences contained in the ssODN
repair templates were altered to prevent re-cutting of the edited alleles.
The knock-in efficiencies were quantified by ICC with a V5-tag
antibody and three distinct delivery strategies were assessed: (1)
transient Cas9- and sgRNA-coding plasmids; (2) in vitro transcribed
(IVT) sgRNA complexed with recombinant Cas9 protein (rCas9-
sgRNA complex); (3) delivery of IVT sgRNA into the Cas9-
expressing NSCs (Fig. 5B). For the delivery of recombinant Cas9
and/or IVT sgRNA, we optimised the transfection protocol using the
Amaxa 4D system (Fig. S11A,B).
Highest levels of knock-in (∼10%) were achieved using the
CAS9-NSCs by transfection of only IVT gRNAs and ssODNs
(Fig. 5C,D), whereas plasmid delivery of all components into wild-
type cells was much lower. However, ∼5% Olig2 V5-positive cells
were achieved when using the pre-assembled rCas9/sgRNA
complex (>5-fold greater than plasmid delivery). This is efficient
enough that clonal lines could be established, and offers greater
flexibility then using the CAS9-NSCs, as any existing NSC line can
be engineered with this approach.
To determine the precise status of each allele, clonal lines were
derived from the bulk population and PCR genotyped (Fig. 5E).
Two out of five V5-positive clones were found to be tagged at each
allele, demonstrating the remarkable power of this approach to
quickly isolate clones with biallelicly tagged proteins. Sanger
sequencing of the PCR products confirmed correct, in-frame
insertion of the V5 tag sequence into Olig2 C-terminus
(Fig. S11C), and ICC indicated complete colocalisation of the V5
tag and Olig2 signals in the established clonal lines (Fig. 5F).
Successful knock-in of the V5 tag was also achieved at
Sox2 locus using both the rCas9/sgRNA complex and CAS9-
NSCs (∼1.5 and 5.5%, respectively) (Fig. S11D). Similar tagging
Table 1. Summary of gene targeting efficiency in mouse NSCs
Identified by genotyping PCR Identified by Sanger sequencing
Targeted gene Transfection Cell number/ Cas9 sgRNA Colonies per Clones Targeted Targeting NHEJ-repair Biallelic mutation
system DNA amount type pair transfection screened clones efficiency (%) second allele efficiency (%)
Olig2 Amaxa 2B 2.106/5 μg Nickase 1-2 >200 112 29 25.9 16 14.3
Cebpb Amaxa 2B 2.106/5 μg Nickase 1-2 >200 88 50 56.8 36 40.9
Ascl1 Amaxa 2B 2.106/5 μg Nickase 1-2 56±16 66 9 13.6 1 1.5
Amaxa 2B 2.106/5 μg WT 1-2 153 86 30 34.9 26 30.2
Sox2 Amaxa 2B 2.106/5 μg Nickase 1-2 102 79 1 1.3 0 0.0
Amaxa 2B 2.106/5 μg WT 1-2 60 48 0 0.0 n/a n/a
Amaxa 2B 2.106/5 μg Nickase 3-4 65 46 2 4.3 1 2.2
Amaxa 2B 2.106/5 μg WT 3-4 59 22 2 9.1 2 9.1
Olig2 Amaxa 4D 4.105/0.7 μg WT 1-2 32±7.2 37 12 32.4 7 18.9
Nfe2l2 Amaxa 4D 4.105/0.7 μg WT 1-2 22 19 1 5.3 0 0.0
Klf7 Amaxa 4D 4.105/0.7 μg WT 1-2 40 39 22 56.4 14 35.9
Rorc Amaxa 4D 4.105/0.7 μg WT 1-2 21 21 9 42.9 7 33.3
Foxj3 Amaxa 4D 4.105/0.7 μg WT 1-2 41 39 8 20.5 5 12.8
Fos Amaxa 4D 4.105/0.7 μg WT 1-2 24 24 3 12.5 1 4.2
Hoxa5 Amaxa 4D 4.105/0.7 μg WT 1-2 55 41 15 36.6 7 17.1
Lhx2 Amaxa 4D 4.105/0.7 μg WT 1-2 52 45 12 26.7 3 22.2
Trp73 Amaxa 4D 4.105/0.7 μg WT 1-2 39 35 9 25.7 7 20.0
Klf6 Amaxa 4D 4.105/0.7 μg WT 1-2 55 47 9 19.1 6 12.8
Hes6 Amaxa 4D 4.105/0.7 μg WT 1-2 24 22 3 13.6 3 13.6
n/a, not applicable; WT, wild type.
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efficiencies were also observed in the primary mouse foetal FNS2
line and in a glioma-initiating line harbouring Ink4a (Cdkn2a,
encoding Ink4a/ARF) and EGFR overexpression (Bruggeman et al.,
2007) (Fig. S11E). Altogether, these results demonstrate that
epitope tags can be effectively knocked into mouse NSC lines
without recourse to any selectable markers, targeting vectors or cell
sorting.
Engineering of glioma driver mutations into human NSCs
Glioblastoma stem cells display molecular and phenotypic
similarities to NSCs and are thought to arise from endogenous
CNS stem or progenitor cells (Stiles and Rowitch, 2008). Thus,
engineering glioma mutations in a stepwise manner or in
combination into genetically normal human NSCs is an attractive
possibility that could open up significant new opportunities for
studying mechanisms involved in brain tumour initiation, growth
and evolution. Building upon the successful demonstration of gene
targeting at the AAVS1 locus (Fig. 1), we next explored whether
disease-relevant knockouts and introduction of point mutations
were possible (Fig. 6).
To demonstrate possibilities for loss-of-function mutations, we
focused on TP53, one of the most frequently mutated tumour
suppressors in human cancers, including the majority of GBMs
(Brennan et al., 2013). We used the same exon-replacement strategy
as described for the mouse NSC lines, in which a vector containing
1 kb long homology arms flanking the Ef1α-PuroR cassette was
used to target TP53 exon 5 (which encodes the DNA-binding
domain of p53) (Fig. 6A). Human NSCs (U3 line) were transfected
with the targeting vector, a pair of sgRNAs and Cas9n plasmids, and
selected 5 days post-transfection. Human NSCs proliferate more
slowly than mouse NSCs, which makes genetic manipulations more
time-consuming. Nevertheless, puromycin-resistant colonies
emerged (Fig. 6B) and clonal lines could be established over a
period of 4-6 weeks. PCR genotyping of the clonal lines confirmed
successful targeting of one TP53 allele by the selection cassette in
∼67% of the cases (n=8/12; Fig. 6C). Importantly, Sanger
sequencing showed the presence of frame-shifting indels in the
non-targeted TP53 allele in the majority of correctly targeted clones
(an exemplar clone is shown; Fig. 6D). Similar high-knockout
efficiencies were also achieved for two independent human foetal
NSC lines (U5 and U3 Hind, not shown). All correctly targeted
clones lacked detectable p53 protein levels byWB and ICC analysis
(Fig. 6C; Fig. S12). As anticipated, increased cell proliferation was
observed following TP53 knockout (Fig. 6E).
To illustrate engineering of candidate gain-of-function oncogenic
mutations, we pursued the delivery of somatic point mutations
affecting H3F3A, which encodes the histone variant H3.3 and
is frequently mutated in paediatric gliomas. Such mutations
Fig. 4. Generation of homozygous
Sox2-mCherry reporter NSC line.
(A) Schematic of the experimental
strategy for knock-in of mCherry reporter
at the Sox2 C terminus. Cells were
transfected with the targeting vector
together with sgRNA pair and Cas9n
plasmids. After 10 days, mCherry-
positive cells were isolated by cell
sorting. (B) Representation of Sox2
targeted locus and PCR-based
genotyping. No promoter sequence is
contained within the targeting vector
(promoterless construct) and therefore
mCherry expression is expected only
when the Sox2 locus is correctly
targeted. sgRNA pair was designed to
cut in the 3′UTRclose to the stop codon.
mCherry was fused to the Sox2 coding
sequence through a flexible peptide
linker (white box). (C) Live images of
sorted cells showing nuclear localised
mCherry signal. Scale bar: 50 µm.
(D) ICC reveals overlap of mCherry and
Sox2 in the nucleus. Scale bar: 50 µm.
(E) PCR genotyping of clonal lines
derived after cell sorting. Homozygous
clone (C11) shows only an upper band
(3.0 kb), whereas heterozygously
targeted clones also show lower, wild-
type band (2.3 kb). (F) Flow cytometry
histogram confirming consistent
mCherry expression in homozygous
Sox2-mCherry clonal line. Parental
NSCs (grey line) were used to set the
gates.
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occur within the N-terminal tail of the histone H3.3 and result in
single amino acid substitutions (either K27M or G34R/V)
(Schwartzentruber et al., 2012; Wu et al., 2012). From a practical
standpoint, the proximity of the mutations to the N terminus proved
useful, as we could test if the mutant alleles could be introduced to
the endogenous gene using the V5 tag as a reporter of successful
knock-in. For this purpose, we used a pair of sgRNAs targeting the
5′UTR region directly upstream of the start codon together with a
targeting vector containing 1 kb long homology arms flanking the
N-terminal tagged versions of the first coding exon (wild type,
K27M or G34R) (Fig. 6F). Targeting efficiencies varied from 0.2 to
0.5% as determined by ICC for the V5 tag (Fig. 6G), with similar
efficiencies being achieved for the other two independent human
cell lines (U5 and U3 Hind, not shown). WB using antibodies
against the V5 tag and histone H3-specific antibodies confirmed the
expected size of the tagged protein (around 17 kDa) (Fig. 6H).
Correct targeting at H3F3A was demonstrated by PCR-based
genotyping using primers lying within the V5 tag sequence and
downstream of the right homology arm (Fig. 6H). Additionally,
Sanger sequencing of the PCR product confirmed the presence of
the expected point mutations in the targeted cells (Fig. 6I).
DISCUSSION
New tools and strategies that enable precise genetic manipulations
in NSCs are highly desirable and would open up considerable new
opportunities for discovery across stem cell biology, regenerative
medicine, neuroscience and related fields. However, targeted
genetic manipulations using HR – the mainstay of functional
genetic analysis of pluripotent cells – has been technically
challenging in most somatic stem cells, largely owing to practical
constraints limiting the ability to deliver, isolate and clonally expand
cells with the desired genetic change. We reasoned that NSC lines
might be particularly well suited to targeted genetic manipulations,
as they are readily transfectable and can be clonally expanded in
adherent and feeder-free culture conditions. Indeed, we
demonstrated here that mouse and human NSC lines are highly
amenable to a range of precise genetic manipulations facilitated by
the CRISPR/Cas9 technology.
To date, the simplest application of CRISPR/Cas9 in mammalian
cells, including mouse neural precursors in vivo, has been to disrupt
gene function through the generation of random indel mutations
(Chen et al., 2015; Kalebic et al., 2016). This is clearly an important
application and is particularly well suited to genome-wide
screening, as demonstrated recently in human NSC cultures
(Toledo et al., 2015). We confirmed that this works well for
mouse NSC lines using transient plasmid delivery of CRISPR/Cas9
components followed by FACS-based enrichment of transfected
cells. NHEJ-mediated gene disruption was also highly efficient
when using the mouse Rosa26-Cas9 NSC line (CAS9-NS), which
avoids the need for FACS and has particular value for genetic
screenings using pooled libraries of CRISPR sgRNAs, as
previously achieved in mouse ESCs (Koike-Yusa et al., 2013).
However, the obvious limitations of gene disruption via indel
formation is the lack of control over the types of mutations that
emerge and a requirement for screening large numbers of clones to
identify the desired loss-of-function mutants. Following the
Fig. 5. CRISPR/Cas9-based gene targeting enables
epitope tagging of endogenous transcription factor
genes. (A) Representation of strategy to knock in the V5 tag
in-frame into the Olig2 C terminus using a single-stranded
oligonucleotide DNA (ssODN) as a donor template. V5 tag
sequence is shown in green, homology arms in grey and stop
codon in black. Yellow triangle represents the sgRNA target
site (sgRNA-3) at Olig2 3′UTR. (B) Schematic depicting the
three strategies employed for the knock-in of the V5 epitope
tag: (a) delivery of plasmids encoding sgRNA and Cas9-2A-
GFP followed by FACS enrichment; (b) delivery of a
ribonucleoprotein complex made by conjugating in vitro
transcribed (IVT) sgRNA and recombinant Cas9 protein
(rCas9); (c) delivery of IVT sgRNA into the CAS9 NSCs
(constitute Cas9 expressing from Rosa26).
(C) Representative image of V5-tagged Olig2 cells
(arrowheads) identified using ICC against the V5 tag. DAPI
was used for nuclear staining. Scale bar: 50 µm.
(D) Quantification of Olig2-V5-positive cells using the three
delivery strategies (shown in B). Values represent the
percentage of V5-positive cells relative to total DAPI nuclear
counting. (E) PCR-based genotyping of representative v5-
Olig2 clones derived from the bulk cells transfected with
rCas9+IVT sgRNA complex. PCR1 used primers within the
V5 sequence and outside the R-HA. Homozygosity was
confirmed using primers flanking the V5 insertion site (PCR2).
Homozygous targeted clones (A1 and A4) were identified by a
single upper band 42 bp higher than the control, WT band.
Clones displaying two bands were considered as
heterozygous. (F) ICC for the V5 tag and Olig2 in
homozygously tagged clonal lines. As anticipated, V5 staining
is nuclear localised and overlaps with native Olig2 staining.
Scale bar: 50 µm.
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demonstration of transgene insertion via HR at safe harbour loci, we
deemed it important to explore whether gene disruption in NSC
lines could be achieved via gene targeting, as originally developed
in mouse ESCs (Capecchi, 2005). Using an exon-replacement
approach recently devised for human iPSCs (W.C.S., unpublished),
we demonstrate that mouse NSC lines are highly amenable to gene
knockout via HR, with truly remarkable efficiencies of biallelic
knockout possible.
Although we did not observe biallelic targeting – i.e. both alleles
undergoing successful replacement by HR – we did consistently
observe monoallelicly targeted clones harbouring indel mutations
on the non-targeted allele. Although deemed disadvantageous
under certain circumstances (e.g. knock-in of fluorescent reporters;
Merkle et al., 2015), the presence of these indel mutations has
considerable practical value as it enables a single round of targeting
and selection to virtually guarantee isolation of loss-of-function
mutant clones. Moreover, owing to the random nature of the indels,
this offers a platform for simple generation of partial loss-of-
function (hypomorphic), or, less frequently, gain-of-function (e.g.
dominant-negative) alleles in a controllable manner. As only one
allele is left after the HR event (i.e. cells are hemizygous), studying
the resulting allelic series of distinct clonal lines can offer valuable
insights into specific residues or domains of interest. Indeed,
sgRNAs might be specifically designed with this purpose in mind,
e.g. to probe protein or DNA interaction domains, phosphorylation
sites, etc.
To open up possibilities for higher throughput production of
mutants, we successfully optimised the transfection protocols,
scaling down the amount of cells and DNA used. Remarkably,
mutation of 11 transcription factors in NSCs was achieved in only a
few weeks (plus∼2 weeks for targeting vector construction) using a
single round of 16 transfections in parallel. From a practical
standpoint, this means typically only a handful of NSC colonies
need to be picked and screened to isolate biallelic mutants, thereby
significantly accelerating precise genetic modification of NSCs.
These findings are particularly timely, as the plummeting costs of
DNA synthesis now enables rapid production of bespoke and
elaborate targeting vectors in weeks rather than months.
Furthermore, direct engineering of NSCs is advantageous, as it
sidesteps the need for ESC or iPSC modification and subsequent
differentiation, which can be laborious and problematic, particularly
if the gene of interest is required earlier in development.
Our optimised protocols for efficient gene targeting in mouse
NSC lines led us to attempt the more challenging production of
knock-in alleles. We focused on generation of fusions of either
fluorescent proteins or peptide epitope tags. The knock-in of a
fluorescent reporter for Sox2 – a highly expressed gene in NSCs –
was remarkably efficient, highlighting the value of flow cytometry
and use of promoterless targeting vectors to enrich biallelic targeted
cells. Monitoring protein levels and localisation in live cells using
endogenous regulatory elements is therefore now possible and will
greatly facilitate functional studies. Complementary epitope tagging
of endogenous genes can now simplify protein interaction studies
and mapping of genome-bound sites using immunoprecipitation in
combination with mass spectrometry (IP-MS) or chromatin
immunoprecipitation combined with sequencing (ChIP-Seq),
Fig. 6. Delivery of glioma-relevant mutations into genetically normal human NSCs. (A) Schematic depiction of the targeting strategy to knock out TP53 via
gene targeting. CRISPR sgRNA pair targeting site is indicated with a yellow triangle. Horizontal arrows indicate PCR genotyping primers for assaying TP53 locus
targeting (PCR1 and PCR2) and presence of an indel within the second allele (PCR3). (B) Representative phase contrast images of puromycin-resistant human
NSC colony after 10 days of selection. Right-hand image is a magnification of the boxed area on the left. Scale bar: 100 µm. (C) PCR-based genotyping (top) and
WB analysis (bottom) of human TP53 targeted NSC clonal lines. Parental, non-transfected cells were used as a control. (D) Sanger sequencing trace of an
exemplar correctly targeted clone harbouring an 85 bp deletion on the second allele. (E) Growth curve analysis of the TP53 targeted clones harbouring the 85 bp
deletion confirming the positive proliferative effect of p53 ablation. (F) Illustration of the strategy for gene targeting the first H3F3A coding exon. Yellow triangle
indicates sgRNA pair targeting site. Horizontal arrows indicate PCR genotyping primers. (G) ICC using a V5 tag-specific antibody to identify targeted cells
(arrowheads). DAPI was used for nuclear staining. Scale bar: 50 µm. (H)Western blotting using V5 tag and histone H3-specific antibodies and PCR genotyping of
parental and transfected cells. (I) Sanger sequencing traces of the genotyping PCR products confirm presence of the point mutations in the V5 tag-positive cells.
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respectively. This will be a massive boost for investigators who are
frequently hampered by the limitations of poor quality, non-specific
or unavailable antibodies. We found that such knock-in of epitope
tags can be rapidly implemented in NSCs, and our data suggest that
delivery is most efficient using recombinant Cas9 protein/gRNA
complex into NSC cultures. Notably, efficiencies are high enough
that cell sorting or drug selection strategies are not required.
The ability to manipulate the NSC genome precisely also has
great potential in neuro-oncology. There is now a clear opportunity
to engineer candidate driver mutations or epimutations uncovered in
genome sequencing projects. We illustrated this by successful
mutation of the endogenous TP53 and H3F3A loci in genetically
normal human NSC lines. It should now be possible to test the
effects of glioma mutations, step-wise and in combination, across a
range of spatially and temporally diverse NSCs cultures; and vice
versa, efficient gene targeting could now enable gene correction of
putative driver mutations in patient-derived GBM cell lines.
Together, both approaches create useful isogenic panels of human
cellular models for brain tumour research – an important
requirement for effective cell-based phenotypic screening.
Risks of off-target mutations with CRISPR are often discussed
(Tsai and Joung, 2016). However, for in vitro cell lines – as opposed
to genome editing in embryos – potential off-target mutations are
less of a concern, as one can generate multiple clones using different
sgRNAs and also readily perform genetic rescue to provide
confidence in any newly identified cellular phenotype. When
unique sgRNAs are unavailable, then use of Cas9 nickase reduces
the risk of off-target mutations (Cho et al., 2014). Nonetheless, the
most recent studies exploring CRISPR-Cas9 off-target effects have
not identified significant issues when sgRNAs with unique targets
are used (Kim et al., 2016) and therefore initial fears of widespread
off-target damage have now waned.
The CRISPR/Cas9 technology has rapidly transformed
possibilities for mammalian functional genetics. We can finally
move beyond transformed cell lines such as HeLa (Hyman and
Simons, 2011) into a new era of systematic functional gene
annotation, with multiple genes or pathways being explored in
parallel in relevant primary cells. In summary, our findings indicate
that targeted, precise and complex genetic manipulations can be
readily performed in NSC lines. Genetic control of NSC self-renewal
can now investigated using elegant genetic strategies that have been
so successful in understanding ESCs (Martello and Smith, 2014).
This opens up a wealth of opportunities to explore gene function in
CNS development, adult homeostasis and pathological processes.
MATERIALS AND METHODS
Design and construction of CRISPR sgRNAs and targeting
vectors
CRISPR sgRNAs were designed using the Optimized CRISPR Design tool
(http://crispr.mit.edu). Predicted sgRNA off-target sites were retrospectively
analysed using the WTSI Genome Editing tool (http://www.sanger.ac.uk/
htgt/wge). All sgRNAs were predicted to target unique genomic sites. For
the majority of those, similar sequences contained mismatches of three or
more nucleotides (with at least one occurring in the PAM proximal region),
and therefore off-target cleavage is unlikely (Cho et al., 2014). Sequences
are provided in Table S1.
For sgRNA-encoding plasmids, single-stranded oligonucleotides
(Integrated DNA Technologies) containing the guide sequence of the
sgRNAs were annealed, phosphorylated and ligated into BsaI site of U6-
BsaI-sgRNA backbone (kindly provided by S. Gerety, Sanger Institute,
Cambridge, UK). For in vitro transcription (IVT), dsDNA templates for T7-
driven transcription were generated by annealing two oligonucleotides – one
containing the T7 promoter and guide RNA target sequences, and the other
containing the Cas9-binding tracrRNA sequence. The annealed oligo pair
was gap-filled using T4 DNA polymerase, column-purified, and then used
as a template for IVT (MEGAscript T7 Transcription Kit). The RNA was
purified using MEGAclear Transcription Clean-Up Kit.
Targeting vectors were constructed via Gibson assembly and Gateway
cloning (Fig. S3). Briefly, linearised backbone and a Zeo/PheS bacterial
selection cassette were obtained through EcoRV digestion of existing
plasmids. Homology arms of ∼1 kb were amplified from genomic DNA
using PCR primers with 22 bp overhangs compatible with both backbone
and the Zeo/PheS double-selection cassette. Gibson reactions were
performed using a standard protocol with home-made enzyme mix
(Gibson et al., 2009) to create the intermediate Gateway cloning
compatible intermediate vector. The Zeo/PheS cassette was replaced via
LR Gateway cloning using a FRT-Ef1a-PuroR-FRT mammalian selection
cassette. For AAVS1 and Rosa26 targeting vectors, the Luc-2A-GFP, Cas9-
2A-GFP or rtTA expression cassettes were PCR amplified from existing
plasmids (gift from M. Pule, University College London, UK) and cloned
into Gateway pDONR221 using BP cloning. The cassettes were then
delivery into the intermediate targeting vectors via Gateway LR cloning.
Construction of the AAVS1-TRE-GFP targeting vector involved restriction
digestion followed by ligation of a custom gene vector (Life Technologies)
containing the TRE-GFP-2A-PuroR cassette into the digested AAVS1
intermediate targeting vector (Fig. S3). For mouse Sox2-mCherry targeting
vector, 1 kb long arms were PCR amplified and tethered to mCherry
sequence using Gibson reaction. The sgRNA targeting region was removed
from the R-HA in targeting vector to avoid re-cutting of residual Cas9 after
the homologous recombination event. For H3F3A targeting vectors,
homology arms were amplified from genomic DNA and Gibson-
assembled with synthetic DNA fragments (Life Technologies) containing
the V5-tagged, mutant sequences of the first coding exon.
Plasmid encoded- and recombinant Cas9
Human codon-optimised Streptococcus pyogenes wild-type Cas9 (Cas9-
2A-GFP) and Cas9 nickase (Cas9n-2A-GFP) plasmids were obtained from
Addgene (#44719 and #44720). Recombinant wild-type Cas9 was
purchased from PNA Bio.
Cell culture
Mouse adult NS line (ANS4) was derived from the subventricular zone as
previously described (Pollard et al., 2006). Mouse foetal NSC lines FNS2
and PG1-1 were derived from the telencephalon region of embryonic day
11.5 and 17.5 embryos, respectively. Human lines were derived from the
telencephalon of ∼8-week-old human fetal material. The human fetal
material used to derive U3 and U5 cell lines was provided by the Joint MRC/
Wellcome Trust (grant number 099175/Z/12/Z) Human Developmental
Biology Resource (www.hdbr.org). Tissue was donated with
informed consent after elective termination of pregnancy. Detailed
protocols for derivation of mouse and human foetal cell lines are
described elsewhere (Conti et al., 2005; Sun et al., 2008). RNA-seq
profiling of human NSCs confirmed expression of NS affiliated lineage
marker. Genomic profiling of these lines using GeneChip SNP 6.0 arrays
(Affymetrix) did not identify any structural genetic alterations (not shown).
Mouse and human lines were expanded for more than 15 passages before
use in gene-targeting experiments. Established lines were propagated in
serum-free basal medium supplemented with N2 and B27 (Life
Technologies), laminin (Sigma, 1 µg/ml) and growth factors EGF and
FGF2 (Peprotech, 10 ng/ml). Mediumwas changed every 2-3 days and cells
split 1:3 or 1:5 once per week after dissociation with Accutase solution
(Sigma). Laminin was added directly to the culture media, with no need for
pre-coating of flasks. This improved colony formation and simplified
screening. Colonies were picked by manual aspiration using a 20 µl pipette.
Confluence analysis and growth curves were determined using Incucyte
(Essen Bioscience) live cell imaging system.
Cell transfection
Cells were transfected using either Amaxa 2B or 4D nucleofection systems
(Lonza) according to the manufacturer’s instructions. For the 2B system,
2×106 cells were pre-mixed with plasmid DNA, 2 µg of the indicated Cas9
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vector, 1 µg of each sgRNA and 1 µg of the targeting vector or 2 µg of ssODN
in 100 µl of Neural Stem Cell Amaxa nucleofection buffer. Nucleofection
program T-030 and X-005 was used for mouse and human NSCs,
respectively. For the 4D system, 16-strip cuvettes were loaded with, unless
otherwise stated, 4×105 cells and 0.8 µg plasmid DNA (0.4 µg Cas9, 0.1 µg
each sgRNA and 0.2 µg targeting vector) in SG transfection solution (Lonza).
Program DN100 gave best survival and transfection efficiency for plasmid
DNA delivery. For delivery of the Cas9/sgRNA complex, 5 µg (unless
otherwise stated) of recombinant Cas9 were mixed with 3 µg of in vitro-
transcribed sgRNA and allowed to form ribonucleoprotein complex at room
temperature for 10 min. The Cas9/sgRNA complex together with 1.5 µg of
ssODNwas transfected into 2×105 cells using the Amaxa 4D16-strip cuvettes
in SG transfection buffer. Program EN138 gave the best results for rCas9/IVT
sgRNA delivery. After transfection, cells were recovered in pre-warmed
culture media and plated onto 10 cm culture dishes for 5 days prior to drug
selection or downstream assays.
T7 endonuclease I assay
Genomic regions flanking the CRISPR sgRNA target sites were PCR
amplified using gene-specific primers (Table S2). PCR products were
purified with MinElute PCR Purification Kit (Qiagen) and hybridised in
NEB buffer 2 (95°C, 5 min; 95-85°C at −2°C/s; 85-25°C at −0.1°C/s; hold
at 4°C). After treatment with T7 endonuclease I (5 U, NEB) at 37°C for 1 h,
the resulting fragments were subjected to electrophoresis in a 2.5% agarose
gel and visualised by staining with ethidium bromide. Cleavage
quantification was based on relative band intensities using ImageJ.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde, permeabilised and blocked in 0.1%
bovine serum albumin plus 3% goat serum solution. Samples were incubated
overnight with primary antibodies followed by incubation with appropriate
secondary antibodies (1:1000; Invitrogen) and 4′,6-diamidino-2-phenylindole
(DAPI). Immunopositive cells were quantified using ∼5000 cells (minimum
of ten random fields). Total cell number was determined by DAPI nuclear
staining. The following primary antibodies were used: mouse nestin (1:10;
Developmental Studies Hybridoma Bank, Rat-401), human nestin (1:500;
R&D Systems, MAB1259), mouse Sox2 (1:100; Abcam, 92494), human
Sox2 (1:50; R&DSystems, MAB2018), BLBP (also known as Fabp7) (1:200;
Santa Cruz, sc-30088), GFAP (1:1000; Sigma, G3893), Tuj1 (also known as
Tubb3) (1:1000; Biolegend, 801202), GFP (1:1000; Abcam, AB13970),
Olig2 (1:400; Millipore, AB9610), mCherry (1:500; Abcam, AB167453), V5
tag (1:1000; eBioscience, 14679682), p53 (1:400; Cell Signaling, 2524).
Western immunoblotting
Immunoblotting was performed using standard protocols. Antibodies were
diluted in 5% milk powder in TBS-T, and protein detection was carried out
with horseradish peroxidase-coupled secondary antibodies (ThermoFisher
Scientific, A16110 and A16072) and exposed to X-ray film. The following
primary antibodies were used: Olig2 (1:3000; Millipore, AB9610), GAPDH
(1:1000; GenTex, GTX627408), p53 (1:500; Cell Signaling, 2524), V5 tag
(1:1000; eBioscience, 14679682); histone H3 (1:2000; Abcam, AB24834).
Drug selection and clonal expansion
Cells with stable targeting vector integration were selected using 5 µg/ml
blastidicin or 0.1 µg/ml puromycin. Selection commenced 5 days post-
nucleofection to enable time for expression of Cas9, HR and expression of
selection cassettes. After 7-10 days of blasticidin selection, Rosa26 and
AAVS1 targeted cells were enriched by FACS (GFP expression) and plated at
<5000 cells/10 cm dish for recovery of colonies. For the knockout
experiments, cells were kept in puromycin for 7 days. Resistant colonies
were individually picked into 2×24 or 96-well replica plates and expanded
for cell banking and DNA extraction. Cells for genomic DNA extraction
were cultured until >90% confluent.
PCR-based genotyping of targeted clones
Genomic DNA was isolated from each well of a confluent 24- or 96-well
plate as follows: cells were incubated for 2 h at 55°C in 20 or 40 μl of lysis
buffer (0.45% NP40, 0.45% Tween20, 1× NEB LongAmp PCR buffer) and
subsequently heated to 95°C (10 min). One to two microlitres of this lysate
was used in a 10 μl PCR reaction. PCR reactions comprised 0.2 μl DMSO
(100% v/v, Sigma), 0.3 μl dNTPs (10 mM, Thermo Fisher Scientific), 2.0 μl
LongAMP buffer (5× NEB), 0.4 μl LongAMP Taq (NEB) and 12 pmol of
each primer. Thermal cycling was performed using the following
conditions: 1 cycle 94°C for 3 min; 40 cycles 94°C for 15 s, 60°C for
30 s, 65°C for 2 min; followed by final extension at 65°C for 10 min.
For each targeted locus, two sets of genotyping primers spanning the
junction of genomic sequences and targeting vector were used (left and right
arms). Gene-specific primers were designed outside the 5′ and 3′ homology
arms and were used in combination with primers in the knock-in cassette
(either CAG-LUC-2A-GFP-IRES-BSD for targeting Rosa26 and AAVS1
loci, or Ef1α-Puromycin for the knockout experiments). To identify NHEJ-
based indel formation on the second, non-targeted alleles, the region
flanking the sgRNA target sites (500-600 bp) was amplified using PCRwith
gene-specific primers and directly assessed by Sanger sequencing.
Sequences of all primers are provided (Table S2).
qPCR copy number analysis
Quantitative PCR with the TaqMan Copy Number Assay (Applied
Biosystems) was performed as previously described (Schick et al., 2016). A
custom Puromycin-resistance gene (PuroR) probe was used with reference
Tfrc (4458367). Genomic DNA from a mouse ESC line harbouring a single
genomic copy of GFP-IRES-PuroR (TNG; gift from Ian Chambers,
University of Edinburgh, UK) was used as calibrator sample.
qRT-PCR
RNAwas extracted using the RNeasy spin column kit (Qiagen), plus DNase
treatment to eliminate gDNA. cDNA was generated with SuperScript III
(Invitrogen), and quantitative RT-PCR was performed using Taqman
Universal PCR Master Mix (Applied Biosystems). The following Taqman
assays (Life Technologies) were used: mOlig2 (Mm01210556_m1),
mGAPDH (Mm99999915_g1), hTP53 (Hs01034249_m1) and hGAPDH
(Hs02758991_g1).
Metaphase spread
For karyotyping, cells were treated with nocodazole (5 h) and metaphase
spreads prepared as previously described (Campos et al., 2009). Modal
chromosomal number of the parental and clonal lines was determined by
counting chromosomes of at least 20 mitotic cells.
Differentiation assay
Glial and neuronal differentiation was initiated by removing EGF from the
culture media for 3 or 7 days (mouse and human, respectively). Cells were
then allowed to differentiate in the presence of 1% foetal calf serum for an
additional 3 or 14 days. For differentiation of mouse PG1-1 cells into
oligodendrocyte precursors, EGF was removed from the media for 4 days.
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Figure S1 | Characterisation of parental mouse and human NS cell lines used 
in the study. 
(A) Newly derived mouse and human NS cell lines (ANS4 and U3, respectively) 
displayed the characteristic NS cell morphology and uniformly expressed the defining 
NS markers Sox2 and Nestin as well as the radial glia marker BLBP. Analysis of 
metaphase spreads indicated normal chromosomal number after culture expansion 
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of both lines (modal chromosomal number = 40 in mouse cells and = 46 in human 
cells). Mouse and human lines were analyzed at passage 25 and 14, respectively. 
(C) In differentiation conditions (see methods) astrocytes and neurons emerge, as 
shown by ICC and qPCR for the lineage markers GFAP (astrocyte) and TuJ-1 
(neurons). 
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Figure S2 | Characterisation of mouse Rosa26 and human AAVS1 edited NS 
clonal lines. 
(A) General PCR-based genotyping strategy for determining correct gene targeting at 
Rosa26 and AAVS1, and representative genotyping results of clonal lines derived 
from the GFP sorted population. Biallelic targeting was not achieved, as PCR with 
primer set 3 was in all cases able to amplify the non-targeted allele. 
(B) Targeting at Rosa26 in the primary foetal mouse NS cell (FNS2). 
(C) PCR-based strategy to detect vector backbone sequences in correctly targeted 
clones, and exemplar results of Rosa26-Luc-GFP mouse clonal lines. Mouse ES cell 
line TNG (Nanog-GFP-IRES-Puromycin) was used as control. 
(D) Summary of GFP copy number analysis using quantitative PCR in Rosa26-Luc-
GFP mouse clonal lines. 9/11 clones were shown to contain a single copy integrated 
in the genome. 
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(E) Growth curves of mouse and human clonal NS lines targeted with LUC-GFP 
cassette at Rosa26 and AAVS1 loci demonstrate similarly doubling time to unedited 
controls.   
(F) Edited clonal lines displayed typical NS cell morphology, uniformly expressed the 
NS markers Nestin and Sox2 (left) and maintained diploid karyotype (modal 
chromosome number of 40 and 46 for mouse and human, respectively) as well as 
glial and neuronal differentiation potential (right). 
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Figure S3 | General strategy for construction of Gateway compatible targeting 
vectors and generation of Dox-inducible GFP human NS cells by gene 
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targeting at AAVS1. 
 (A) Construction of intermediate targeting vectors (left panel) involved PCR 
amplification of homology arms, followed by Gibson assembly of a Gateway 
compatible vector containing the bacterial double-selection cassette CmR-CcdB. LR 
Gateway reaction (right panel) was then used to exchange the bacterial selection by 
a mammalian expression cassette of interest. Empty white boxes represent a generic 
expression cassette. For generation of targeting vectors for the knockout 
experiments, the bacterial Zeo-PheS double-selection cassette was used in the 
intermediate vectors and Ef1a-Puro cassette introduced by LR-Gateway into the final 
vector (see Material and Methods). 
(B) Experimental strategy for biallelic knockin at AAVS1 in human NS cells. Cells 
were transfected with two targeting vectors together with sgRNA1 and Cas9 
expression plasmids. Cells targeted with both constructs were selected with 
puromycin in the presence of Doxycyclin (DOX). 
(C) Schematic representation of the AAVS1 targeting vectors containing the 
components of the Tet-On inducible expression system. rtTA was introduced in one 
intermediate vector through LR Gateway cloning, while a second vector containing 
the TRE driving expression of GFP-2A-Puro was generated through conventional 
cloning (see details in Materials and Methods).  
(D) Live cell imaging of drug-selected cells in the presence and absence of DOX, 
confirming functionality of the Tet-on inducible system in human NS cells. Scale bar 
100 um 
Development 144: doi:10.1242/dev.140855: Supplementary information
D
ev
el
o
pm
en
t •
 S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Figure S4 | Olig2 knockout in mouse NS cells using CRISPR/Cas9-induced 
NHEJ. 
(A) Efficient biallelic knockout of Olig2 using transient plasmid delivery of Cas9n-2A-
GFP and sgRNA pair in primary foetal forebrain mouse NS cells (FNS2).  White 
arrows indicate Olig2-negative cells. Plot shows percentage of negative cells in 
relation to the total DAPI-stained nuclei. Scale bar: 50 µm. 
(B) Delivery of wild type Cas9 and individual sgRNAs resulted in relatively higher 
Olig2 knockout efficiencies in the mouse NS cell line ANS4 following GFP-sorting. 
White arrows indicate Olig2-negative cells. Plot shows percentage of negative cells 
in relation to the total DAPI-stained nuclei. Scale bar: 50 µm. 
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Figure S5 | Characterisation of Olig2 mutant mouse NS clonal lines generated 
via CRISPR/Cas9-assisted gene targeting 
(A) qPCR and Western blotting confirmed complete ablation of Olig2 protein, but not 
mRNA levels, in clonal lines harboring frame shifting indels on the second allele. 
Parental cells and targeted clones with non-mutated second alleles were used for 
comparison. 
(B) Olig2 mutant clonal lines maintained a normal karyotype as determined by 
metaphases spread (modal chromosomal number = 40; n = 20-30), typical NS 
morphology and expression of Nestin (middle lanes) and proliferated normally under 
optimal self-renewing conditions (bottom lane). Blue lines represent the confluence 
curves of the indicated clones. Growth of parental cells (grey line) is shown for 
comparison. 
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Figure S6 | Summary of copy number analysis of puromycin-resistance gene 
in mouse clonal lines.  
(A) Quantitative PCR analysis using Taqman Copy number assay determining the 
number of genomic copies of puromycin-resistance cassette in mouse targeted 
clonal lines. Approximately seventy-five percent of clones showed a single copy 
insertion.  
(B) Exemplar mixed sequencing trace of the non-targeted allele from a CebpB-
targeted mosaic colony. 
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Figure S7 | Olig2 targeting in a mouse foetal PDGFRa H2B-GFP reporter NS cell 
line. Following transfection with Olig2 targeting vector and CRISPR sgRNAs, 
puromycin-resistant colonies were differentiated for 4 days in the absence of EGF. 
Olig2-negative colonies did not generate GFP-positive, oligodendrocyte precursor-
like cells. 
Development 144: doi:10.1242/dev.140855: Supplementary information
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 Figure S8 | Representative indels found in the second alleles of the 14 
successfully targeted genes. Sanger sequencing traces identify the status of the 
genomic sequence around the target site of the sgRNA pairs used in the knockout 
experiments. Targeted gene exons can be identified by the Ensembl exon accession 
number shown at the top right corner of each box. 
Development 144: doi:10.1242/dev.140855: Supplementary information
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Figure S9 | Optimization of the 4D Amaxa nucleofection system for gene 
knockout via CRISPR/Cas9 assisted gene targeting. 
 (A) Optimisation of transfection buffer and nucleofection program using a GFP 
expression plasmid. Solution G and program DN100 produced the maximal results in 
terms of cell survival and transfection efficiency.  
(B) Olig2 gene targeting in mouse NS cells using the optimized transfection protocol. 
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Left - Targeting and genotyping  strategy used (same as in Fig.3). Right - puromycin-
resistant colony counts and PCR genotyping results after transfection of different cell 
amounts and Cas9 type. 
(C) Exemplar genotyping results of puromycin-resistant colonies following Amaxa 4D 
transfection using WTCas9 and 400k cells. 
(D) qPRC copy number analysis of puromycin-resistant gene in Olig2 correctly 
targeted clonal lines obtained with Amaxa 4D transfection system.  
Development 144: doi:10.1242/dev.140855: Supplementary information
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Figure S10| Characterization of mouse Sox2-mCherry reporter NS cell line. 
(A) FACS plot indicating the percentage of mCherry positive cells 10 days post-
transfection with a promoterless Sox2-mCherry targeting vector. Parental, non-
transfected cells were used to set the gates. SSC, side scatter.  
(B) ICC analysis confirmed co-localization of mCherry and Sox2 staining in the 
sorted but not in the parental cells. DAPI counterstaining was used to highlight 
nuclear localization of Sox2-mCherry staining. 
(C) Growth curves of parental ANS4 (grey line) and homozygously targeted Sox-
mCherry clonal line (red). 
(D) Sox2-mCherry clonal line maintained normal NS morphology, uniform 
expression of nestin and diploid karyotype (modal chromosomal number = 40). 
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Figure S11 | Epitope tagging in mouse NS cells using single-strand DNA 
oligonucleotides as donor templates. 
(A) Optimization of rCas9/IVT sgRNA delivery for Olig2 tagging using the Amaxa 4D 
system. 15 transfection programs were tested in SG cell line buffer and knock-in 
efficiencies quantified by V5 ICC. Program EN-138 shows maximum efficiency and 
was used for rCas9/IVT sgRNA delivery in all experiments. 
(B) Varying amounts of rCas9 were compared for transfection and Olig2 V5 knock-in 
efficiency. 
(C) Sanger sequencing confirms correct, in frame insertion of the V5 tag into Olig2 
C’terminus in homozygously tagged clonal line. Different features are highlighted in 
the sequence shown; Olig2 coding region (grey), V5-tag sequence (green), stop 
Development 144: doi:10.1242/dev.140855: Supplementary information
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condon (bold black), PAM (red) and sgRNA sequence (blue). Note that PAM 
sequence was disrupted to avoid re-cutting after the HR event. 
(D) Efficiencies of V5 tagging of Sox2 in mouse NS cells using the different delivery 
methods. Tagged cells were identified by V5 staining (indicated by the white arrows). 
(E) Efficiencies of V5 tagging for Olig2 and Sox2 using rCas9/sgRNA delivery in two 
independent mouse NS cell lines. FNS – primary foetal forebrain NS cell line; IENS – 
tumour initiating mouse NS cell line. 
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Figure S12 | P53 expression in TP53-deleted human NS cell clonal line. Phase 
contrast images and P53 staining of parental human NS cells and representative 
TP53 deleted clonal line. Plot shows levels of TP53 mRNA levels assayed by qPCR. 
Scale bar: 100um 
Development 144: doi:10.1242/dev.140855: Supplementary information
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1Table S1. List of sgRNAs used in this study. 
Gene sgRNA ID Guide sequence (5' to 3') PAM Strand Species
Olig2 Olig2-1 GCCCATGGCCCCTCGTAGCT CGG - M. musculus
Olig2 Olig2-2 GCTGAGCTCCGAGCTACGAG GGG + M. musculus
Olig2 Olig2-3 TCTCCAGGACGCACCCCCGC TGG - M. musculus
CebpB CebpB-1 GTCGGGCTCGTAGTAGAAGT TGG - M. musculus
CebpB CebpB-2 GCCCGACTGCCTGGCCTACG GGG + M. musculus
Ascl1 Ascl1-1 GACTTGTGACCGCCCCCTGA GGG - M. musculus
Ascl1 Ascl1-2 GACAGCCAGCCCTCAGGGGG CGG + M. musculus
Sox2 Sox2-1 GTTCACGCCCGCACCCAGGC CGG - M. musculus
Sox2 Sox2-2 GTGGGCGCCGGCCTGGGTGC GGG + M. musculus
Sox2 Sox2-3 GGGGCCGCTCTGGTAGTGCT GGG - M. musculus
Sox2 Sox2-4 GTGCCCGGCACGGCCATTAA CGG + M. musculus
Sox2 Sox2-5 CAGCCCTCACATGTGCGACA GGG - M. musculus
Sox2 Sox2-6 GAAAGAGATACAAGGGAATT GGG + M. musculus
Sox2 Sox2-7 CCAGCCCTCACATGTGCGAC AGG - M. musculus
Hes6 Hes6-1 GGTGCACCTCATGCATGCAC TGG - M. musculus
Hes6 Hes6-2 GTACATCCAGTGCATGCATG AGG + M. musculus
Nfe2l2 Nfe2l2-1 GTCAGCCAGCTGCTTGTTTT CGG - M. musculus
Nfe2l2 Nfe2l2-2 GGAAGCCACACTGACAGAAA TGG + M. musculus
Klf6 Klf6-1 GCTGTCAAATTTTATCTCAG AGG - M. musculus
Klf6 Klf6-2 GGACCAAATTCATTCTAGCT CGG + M. musculus
Klf7 Klf7-1 GGAGGTAGCGTTCCAACTCA AGG - M. musculus
Klf7 Klf7-2 GACAGAACCCCGGCGGATCT CGG + M. musculus
Rorc Rorc-1 GTGCTGGCATCGGTTGCGGC TGG - M. musculus
Rorc Rorc-2 GCTGCAGAAGTGCCTGGCTC TGG + M. musculus
Foxj3 Foxj3-1 GGCTGCTCTCATGGTGAGCT GGG - M. musculus
Foxj3 Foxj3-2 GATGCTACACAAAATGCACA TGG + M. musculus
Fos Fos-1 GGTGGAGATGGCTGTCACCG TGG - M. musculus
Fos Fos-2 GTGGCTGGTGCAGCCCACTC TGG + M. musculus
Hoxa5 Hoxa5-1 GGAATTCTTTCTCCAGCTCC AGG - M. musculus
Hoxa5 Hoxa5-2 GCTACCTGACCCGCCGAAGA AGG + M. musculus
Lhx2 Lhx2-1 GGCTGTCCTTCATGCCGAAA TGG - M. musculus
Lhx2 Lhx2-2 GGTGATGCGCGCTCGGGACT TGG + M. musculus
Trp73 Trp73-1 GTGGACACTTTGATCTGGAT GGG - M. musculus
Trp73 Trp73-2 GTGTCCACACCACCACCCCC GGG + M. musculus
Rosa26 Rosa26-1 CGCCCATCTTCTAGAAAGAC TGG - M. musculus
Rosa26 Rosa26-2 AGTCTTTCTAGAAGATGGGC GGG + M. musculus
AAVS1 AAVS1-1 GTCACCAATCCTGTCCCTAG TGG - H. sapiens
AAVS1 AAVS1-2 GGGGCCACTAGGGACAGGAT TGG + H. sapiens
H3F3A H3F3A-1 GATCACCCCCTCCCCAAATC TGG - H. sapiens
H3F3A H3F3A-2 GGCAGGAAAAGTTGTATGTT TGG + H. sapiens
TP53 TP53-1 GATGGCCATGGCGCGGACGC GGG - H. sapiens
TP53 TP53-2 GAGCGCTGCTCAGATAGCGA TGG + H. sapiens
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Forward Reverse Forward Reverse Forward Reverse Forward Reverse Forward Reverse
Olig2 M. musculus CCTCCAGGAAAAGCACATTG CCCAGGGATGATCTAAGCTCT TGCAAGGCAGGTGTTTTCAGT CTGCCAGTGATCACCCAAC AATTAGCCGGGTGACATCAG GCGATCTCTGGGTTCTACGTTAGTG TCTATAGTCGCAGTAGGCGG CAGCTGGGAGGAAAGAAACA CTCTCCTCAAGTTCGGAAGG TGGCGATCTTGGAGAGCTT
CebpB M. musculus GTTAGTGAAGCCCCAACGTC CCCAACTCTTGGGAAACAGA TGAGAACCTTTTCCGTTTCG TGAGAGCCACAAGCTATCCA GCTCACTCTCTGCCTTCCTG AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG ACCCTGTGACAGTGGGAGAC CCTTATAAACCTCCCGCTCG GAGGTCGGAGAGGAAGTCG
Ascl1 M. musculus ACACTTCCCCACACCACTGT ATTTGGTTGAACCCCCTTTC CCCTCTTAGCCCAGAGGAAC GAAAGGCTGTCCGAGAACTG AATGCCCTCCTTTCCCATAG GCGATCTCTGGGTTCTACGTTAGTG CATGTCTGGATCCGGGGGTACCGCGTCGAG
TCCCCAAACTGGTTAGGATAG
A AGAGCTCTGGCAAGATGGAG CTTGCTCATCTTCTTGTTGGC
Sox2 (sgRNAs 1-2) M. musculus GCGACAACAAGAGAAACAAAACTA CTCTTCTTTCTCCCAGCCCTA CTCCATTATGCACAGTTTGAGA AATGTGATGAGAGCGCACAA CATCAGGACTTTCTTCCTTCTCTC AAGGCGCATAACGATACCAC CATGTCTGGATCCGGGGGTACCGCGTCGAG CCCTTCCCAGTACCTTACCC GCTTCCCCCCAACTATTCTC TGATCTCCGAGTTGTGCATC
Sox2 (sgRNAs 3-4) M. musculus GCGACAACAAGAGAAACAAAACTA CTCTTCTTTCTCCCAGCCCTA CTCCATTATGCACAGTTTGAGA AATGTGATGAGAGCGCACAA CATCAGGACTTTCTTCCTTCTCTC AAGGCGCATAACGATACCAC CATGTCTGGATCCGGGGGTACCGCGTCGAG CCCTTCCCAGTACCTTACCC GCTTCCCCCCAACTATTCTC TGATCTCCGAGTTGTGCATC
Hes6 M. musculus AATGGATGGGTGAAGAGGTGGG GACACAGTAGCGTGTCCCGTTC CTCTGTGTTCCCCCACTTTCC ATTATTTCATGCACCCTGCATC CTCGTACTTTCCCCGGACTT AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG TTTGGACCCCAACTTATGGA GCCACGATAGTCACTGCTCA CCGGTTTAGTTCAGCCTCTG
Nfe2l2 M. musculus CCCACATTCCCAAACAAGATG CCAAACTTGCTCCATGTCCTG TTATAGCCATGTGTGGCAGTC AGGGCCTTTGTTTTTATTCCC GGGAGGTTATTGCCTAGCAC GCGATCTCTGGGTTCTACGTTAGTG TCTATAGTCGCAGTAGGCGG CCCAGCACCCAACTTTTACA GATTTGGGGGTAGGGAATTG CCGTCCAGGAGTTCAGAGAG
Klf6 M. musculus GAGGCCGGGACTTAGGATGT TTCACCCAACAGGACAGAAAT CATCGTGCTATGTTGGGTTGC TTCTCCTGGGAAAAAGAGCAC GTCTTCGCCATTTCTTTGGA GCGATCTCTGGGTTCTACGTTAGTG CATGTCTGGATCCGGGGGTACCGCGTCGAG CCATGACCCCACACTTCTTT TGACCCACAATACCTGACACA AATTTGGTCGTGGGTGAAAG
Klf7 M. musculus ACAGACACCACATGACTTGC AAATCCATAGAACCCCAACAT TTCCTCTTTTGGGTGTTCCCTT GATAGTGCAGGCCTTTAAGTCC TGAAGCCCAAAGCTGATTTT GCGATCTCTGGGTTCTACGTTAGTG TCTATAGTCGCAGTAGGCGG GCAACTTCCTTGGTGACACA AGTCATTCCATGTGGCCTTG GAGCTCTTCTCGCAGATGGT
Rorc M. musculus CAGTCGTGTCCTGTGCTCATA CAGGGACCTCCAATTCATGTGC TCAAGGCTCTTCAGCCTCTA ACAGCTGAAGAAGGTTCAGGAA CCAGTGCACATGAATTGGAG AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG TCCCAGCTGGAGGAGTCTT GGGGACTTTGGTGGATGTAG GGAGCAGAGCCTGGAGTAGA
Foxj3 M. musculus GGCTGATTTTTGCTATGCTT GAAGAGAGAGGGGAGAAAGGG ATATGGAGACCGAAGGACAAC GCCTCACACTCACAGAGACAT CACAGCTGGAAACTGTTGGA AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG TGCTGAAATGCAAACTCCAG AAGCTTTGCCTCATTTTGGA CAACCACTGCCAGCTTCTCT
Fos M. musculus GCCCAGTGACGTAGGAAGTC TTCCTGTATGCACCTCATCGGA TTGACAGTTGGACCCAAGACA TAAGTAGTGCAGCCCGGAGT GGACCATCTCCGAAATCCTA AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG TTGCCTTCTCTGACTGCTCA GACACTAGGGCCACTTGCTC GCAGTCAGTAGCGTCCCTTC
Hoxa5 M. musculus TACAATGGCATGGATCTCAGC TTAAAGTTCCAGCCGAGCTA TGTAGACCCCAAACCCTCTG TTCAACTCCCAGAGCTCCACGA TAATGGAACTGCGAGGGAAA AAGGCGCATAACGATACCAC CATGTCTGGATCCGGGGGTACCGCGTCGAG CCCGCCTCAATTCAGTCTT CCAGAAAGGAAGGGAGAAGG GTACTTTGGCCGCTCAGATG
Lhx2 M. musculus AGCATAGCTGTAGGCTGTCC CCTGCCTGAAATAGTTTTCC TAGTTCATTGGTGATCCAGG GGCTAGTGGGTGAGCTCTAA AGCTTGGGCCTGGTAGATG AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG CCCTCTTTTTGCTCAGTCACA CAGTGACAGCAACAGCACCT CTGGACTCTTGCGCTTTCTC
Trp73 M. musculus GAGAAACCCTGTCTCGAAAA GACCGTTGCATAAGGATGACA AGCAAGGGTGTAGTCTGAGG ACCGATCATCTCTGTCTTCCC TTCATTGCATTTGCCTATGG AAGGCGCATAACGATACCAC TCTATAGTCGCAGTAGGCGG CCTGTCCCACTGACATTCAA ATCTGAAGCATGCCTGAAGC TTCCTGTGAGGGGAGAGTTG
Rosa26 M. musculus CCGCGGCAGGCCCTCCGA TGCAACTCCAGTCTTTCTAG AGATGGGCGGGAGTCTTCTG CCTGACCTAAGGTCTTGTGA AGAGCCTCGGCTAGGTAG ATTGACGTCAATGGGCGG AGCTTGGCGTAATCATGGTC CCTGAAGAAGCTTGGCAA TAAGGGAGCTGCAGTGGA AGGCGGATCACAAGCAATA
AAVS1 H. sapiens TTACCATCCCTCCCTCGACT CCGAGCTGGGACCACCTTAT TCCTTAGGCCTCCTCCTTCC TAGCACTGAAACCCTCAGTC CCACTCTGTGCTGACCACTC GGGCGTACTTGGCATATGAT TATCCGCTCACAATTCCACA TGACCAACCATCCCTGTTTT CTTGCTTTCTTTGCCTGGAC AGGATCCTCTCTGGCTCCAT
TP53 H. sapiens CCCCTAGCAGAGACCTGTGGGAA GTTGCTTTATCTGTTCACTT TCTGATTCCTCACTGATTGCT ATCCTGAGTAGTGGTAATCTAC GTGAGCGGTGAGACAGTTGTTCTTCCAG GCGATCTCTGGGTTCTACGTTAGTG CATGTCTGGATCCGGGGGTACCGCGTCGAG GTTCTGAAGTTAGTTAGCTACAACCAGGAG T CACCACTGTGCTCCAG GGGAGGTCAAATAAGCAGCA
H3F3A H. sapiens GATAGTTTCCCTGTTCCCTCTG AAGGCACAAACCACTGGAAG ATCCCTAACCCTCTCCTCGGT TAAAATGGTGGGTGGGAAGA n/a n/a ATCCCTAACCCTCTCCTCGGT TCTTCCCACCCACCATTTTA n/a n/a
V5 tag forward
Olig2 C' forward
Olig2 C' reverse
Table S2 - Oligonucleotide primers used in the study
Primers for screening NHEJ allele
Primers used for HDR-based knockout experiments - related to Figure 3 and Table 1          
Primers used for epitope tagging experiments - related to Figure 5
CAG-LUC-2A-GFP-IRES-BSD specific primers 
EF1a-PuroR specific primers
V5 tag specific primers
Gene specific primers
Species
Primers for cloning 5'HA Primers for cloning 3'HA Primers for screening 5' targeting Primers for screening 3' targeting
Locus
V5 tag specific primers
"
ATCCCTAACCCTCTCCTCGGT"
TGTCCTCGGTCGGATCCAT
TTCAAATGCTCCCATTGCTT
Development 144: doi:10.1242/dev.140855: Supplementary information
Table S2. Primer sequences
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